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INTRODUCTION
Follicular lymphoma (FL) has a highly variable clinical course. [1] [2] [3] Whereas some patients do well for decades, often with limited therapy, 30-50% at some point experience histological transformation to a more aggressive lymphoma, usually diffuse large B-cell lymphoma (DLBCL). [4] [5] [6] [7] [8] [9] [10] [11] This transformation, which is thought to reflect the acquisition of new genetic abnormalities leading to further genomic instability, [12] [13] [14] [15] [16] has generally been associated with a poor clinical outcome. 17 Retrospective analyses from the pre-rituximab era have reported a median survival of only 1-2 years after transformation, 18, 19 although a recent prospective observational study suggests somewhat better survival after transformation in the rituximab era. 20 At the present time, the Follicular Lymphoma International Prognostic Index (FLIPI), which integrates patient characteristics at diagnosis, is the gold standard for predicting FL clinical outcome. 21, 22 There is, however, considerable interest in identifying characteristics of the FL cells themselves that might also impact prognosis. 22, 23 The BCL2 gene is critical for FL pathogenesis. 24, 25 Originally identified because of its translocation to the immunoglobulin heavy chain (IGH) locus as a part of the t (14;18) translocation that typifies FL, BCL2 encodes a protein that inhibits apoptosis. 26, 27 In particular, Bcl-2 and related antiapoptotic proteins diminish apoptosis by binding and neutralizing activated proapoptotic Bcl-2 family members, including the mitochondrial outer membrane permeabilizers
Bax and Bak as well as the intracellular stress sensors Bim and Puma, which activate Bax and Bak. [27] [28] [29] Because the IGH locus is activated in B cells, the translocated BCL2 gene is overexpressed in FL cells 25 and enhances their survival. 30 Activation-induced cytidine deaminase (AID), which is highly expressed in germinal center B
cells, introduces mutations into the variable and switch regions of B cell receptor genes during the
For personal use only. on April 29, 2017 . by guest www.bloodjournal.org From 4 physiological process of secondary antibody diversification. 31 After AID deaminates cytidine to uracil, the resulting uracil-guanine mismatches are replicated to produce a C→T transition, a hallmark of AID activity, or removed by uracil DNA glycosylase to create an abasic site that is recognized by nucleases and error prone polymerases, leading to a variety of other mutations or DNA double-strand breaks. 32, 33 In addition to its role in antibody diversification, AID is postulated to play a critical role in lymphomagenesis by mutating genes outside the immunoglobulin locus, 32, 34 including the proto-oncogenes BCL6, PIM1, RhoH/TTF, PAX5, and MYC. 35, 36 Moreover, AID contributes to genetic instability, including the acquisition of chromosomal abnormalities such as IGH translocations. 37, 38 Even though AID levels vary substantially among different FLs, 34 the implications of this variation have been unclear.
At the time BCL2 was cloned, single nucleotide variants (SNVs) were observed in human lymphoma cell lines 39 and a handful of clinical lymphomas 40 compared to normal tissues.
Because these BCL2 variants, like wildtype BCL2, inhibited cell death 41 and facilitated lymphomagenesis, 42 it was assumed that BCL2 mutations do not affect Bcl-2 protein function.
Consistent with this possibility, previous studies showed that the majority of BCL2 mutations in DLBCL are silent 43, 44 and have no effect on survival. 44 More recently, large-scale genomic studies have also identified frequent BCL2 mutations in FL. 16, 45 Whether these BCL2 mutations have a biological impact has been unclear. Our previous studies demonstrated that some mutant Bcl-2 proteins found in lymphoma cell lines exhibit enhanced affinity for proapoptotic Bcl-2 family members and increased ability to protect from death stimuli. 46, 47 Accordingly, the present studies were designed to assess the occurrence, nature and potential clinical importance of mutations in the BCL2 coding sequence in FL.
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METHODS
Patients
Patients with grade 1 and 2 FL who provided written consent for enrollment in the actively maintained Mayo Clinic Lymphoma Database were studied. After approval by the Mayo Clinic IRB, slides from initial diagnostic biopsies and transformation were subjected to pathology review applying WHO criteria. Patients with grade 3 FL were excluded. Three distinct cohorts were studied. Research was conducted in accordance with the Declaration of Helsinki. African American, and 100 Han Chinese) was purchased from the Coriell Institute (Camden, NJ).
Isolation of genomic DNA, sequencing and identification of tumor specific mutations DNA was isolated using a QIAamp DNA kit (Qiagen). For FFPE FL samples, an Illumina Infinium HD FFPE Restore Kit (Illumina) and QIAamp DNA FFPE kit (Qiagen) were used. PCR was performed using primers (Table S1) for exons 1 (discovery cohort only), 2 and 3 of BCL2 (NG_009361.1). PCR products were subjected to Sanger sequencing on both strands using ABI PRISM Big Dye Terminator technology in the Mayo Clinic DNA Sequencing Core. All SNVs were detected in both 3' and 5' directions and confirmed in a separate sequencing reaction using independently amplified DNA. Mixing experiments demonstrated that this approach readily detects variants that are present in ≥ 10% of DNA molecules. Candidate somatic variants (tumor specific) were identified after removing known polymorphisms present in NCBI dbSNP database, HapMap and in our set of normal samples. The absence of the identified mutations in the COSMIC database and in the Cancer Gene Census database was verified. A similar approach was 7 likewise used to sequence the exons of PIM1 using primers in Table S1 .
RNA isolation
RNA was extracted from frozen FL samples using an RNeasy minikit (Qiagen). cDNA was synthesized with Superscript III, amplified with Promega master mix and primers (Table S1) and sequenced as described above. 
AID immunostaining and mRNA detection
Statistical Analysis
Risk of transformation over time and time to transformation (TTT) were estimated as time from diagnosis to histologically proven transformation using Kaplan-Meier methods 48 ; patients without transformation at the time of last follow up or death were censored. The FL-specific survival was estimated as the time from diagnosis to lymphoma-associated death or last follow up using Kaplan-Meier methods. Patients alive at last follow up or with death not lymphoma related were censored. The log-rank test and Fisher's exact test were used to test for association between variables as appropriate. The Cox proportional hazards model was used to evaluate the impact of prognostic variables on TTT and lymphoma-specific survival and to adjust for other known 8 prognostic variables in FLIPI (0-2 vs. 3-4). 49 All p-values were two-sided, and p<0.05 was considered to be statistically significant. All analyses were performed using JMP 9.0 statistical discovery software by SAS.
RESULTS
BCL2 mutation frequency in FL
Based on recent studies reporting frequent BCL2 mutations in FL, 16, 44, 45 as well as our previous studies suggesting that certain Bcl-2 sequence variants found in lymphoma cell lines exhibit enhanced antiapoptotic properties, 46, 47 we examined the occurrence and significance of mutations in the BCL2 coding sequence in FL. In an initial prevalence study, BCL2 exons 1, 2 and 3 were sequenced in cryopreserved FL specimens from 38 FL patients (termed the "discovery" cohort) who had a median age of 64 years, median follow-up of 10.5 years and median survival of 13.2 years. DNA from 300 normal individuals served as a control. We identified lymphoma-specific variants (Table S3) by removing polymorphisms present in the control samples, NCBI dbSNP and HapMap.
A total of 38 SNVs were observed in 20 of 38 discovery cohort samples ( Fig. 1A and Table S3 ). These SNVs were located exclusively within exon 2 and not within the silent exon 1 or within exon 3 that encodes the Bcl-2 transmembrane (TM) domain (Fig. 1B) . To distinguish between rare germline variants and somatic mutations, we sequenced paired DNA samples from peripheral blood mononuclear cells and lymph nodes of 11 FL patients. As illustrated in Fig. 1C for one case, eight of these 11 FLs had SNVs in BCL2 exon 2 that were not present in the corresponding normal cells, indicating that the BCL2 SNVs represent somatic mutations.
To assess whether BCL2 mutations occurred in the translocated alleles, we sequenced cDNA prepared from discovery cohort samples with BCL2 mutations. The mutated message was 9 vastly more abundant than wildtype in all 20 samples containing BCL2 mutations (illustrated in Fig. 1D ), suggesting that the translocated allele is mutated.
To provide a basis for further examination of BCL2 mutations, we also sequenced the PIM1 gene, which is thought (like BCL2) to be a target of AID-induced mutagenesis. In the discovery cohort, only 5 of 39 samples (3 of 20 BCL2-mutant samples) harbored PIM1 mutations.
The discovery cohort had 1.71 x 10 -3 mutations/bp in BCL2 exon 2, a frequency that approaches the IGH mutation rate (5.8 x 10 -3 mutations/bp) during B-cell differentiation (Fig. 1A ) 44, 50 The mutation rate was much lower in other B-cell neoplasms, with BCL2 SNVs in 2 of 117 mucosa-associated, marginal zone and lymphoplasmacytic ("post-follicular") lymphomas; 0 of 36 ALLs; and 2 of 90 CLLs (Fig. 1A) . Moreover, BCL2 was mutated twice as often in FL as in DLBCL (Figs. 1A, 1B and 1D, Table S3 ), consistent with earlier results. 44, 50 Of the 39
DLBCLs examined, 23 were positive for Ig-BCL2 rearrangements involving the major breakpoint region (21) or minor cluster region (2), respectively. Nineteen BCL2 mutations occurred in BCL2-rearranged cases and 3 mutations occurred in non-rearranged cases ( Table S3) .
Presence of BCL2 mutations in FL at diagnosis
The discovery cohort contained samples collected at diagnosis and at relapse after chemotherapy. To rule out the possibility that BCL2 mutations were chemotherapy-induced, as well as provide an opportunity for analyzing the relationship between BCL2 mutations at diagnosis and outcome, BCL2 sequencing was performed on a second, independent cohort pro-apoptotic Bcl-2 family members. [51] [52] [53] 95% of SNVs in the discovery cohort and 71% in the validation cohort occurred at Gs and Cs (Figs. 3A and 3B) . Moreover, 76% and 60% of mutations in the discovery and validation cohorts, respectively, were transitions (C to T or G to A) (Fig. 3B) . This predilection for Gs and Cs, as well as a high transition/transversion ratio, has been observed during AID-induced somatic hypermutation in normal B cells, 31 suggesting that AID might be responsible for the observed BCL2 mutations. Consistent with this possibility, ~40% of FL SNVs occurred at preferred AID target sequences (GCT/A or A/TGC) ( Fig. 3A and Table S4 ) even though AID can also mutate cytidines in other sequence contexts. Moreover, AID sites were not randomly mutated. Instead, mutations were only observed in exon 2 even though 39 preferred AID sites were present in exons 1 and 3 compared with 12 in exon 2 ( Table S4) .
Relationship between AID expression and BCL2 mutations in FL
When AID expression in the FL validation cohort at diagnosis was examined, immunohistochemistry demonstrated substantial inter-sample variability (Fig. 3C) . Similar variability was observed when AID was assessed by RT-PCR (Fig. 3D) . Importantly, AID expression was higher in samples with BCL2 mutations than those without (Fig. 3E, p <0 .0001).
Increased BCL2 mutations at transformation
The presence of the mutagenic AID enzyme in many FLs raised the possibility that BCL2 mutations might continue to accumulate during the course of disease. To assess this possibility, we sequenced BCL2 in 31 available FL pairs, the first collected at diagnosis (part of the validation cohort) and the second a median of 4.5 (range 0.5 -14.5) years later at transformation. In these 31 pairs, the prevalence of BCL2 mutations was 16% at diagnosis and 65% at transformation, (Fig. 4A) . Like mutations at diagnosis, those at transformation were distributed throughout the protein, with a predilection for the FLD (Fig. 4B) and a strong preference for Gs and Cs (79%) (Fig. 4C) . Nonetheless, the mutation signature at transformation was distinct from that at diagnosis (Fig. 3A vs. 4C) , perhaps because 26 of the 31 patients had been treated with radiation or chemotherapy between diagnosis and transformation. Of the 5 FL patients not treated with a DNA damaging therapy prior to transformation, only 2 had BCL2 mutations, a number that is too small to allow derivation of a therapy-independent mutation signature at transformation.
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Some FL BCL2 mutations exhibit gain-of-function
Based on the nonrandom distribution and nonsynonymous nature of FL BCL2 mutations, we have begun to examine the effects of these mutations on Bcl-2 protein function. As illustrated in Fig. 5 for the Bcl-2 G33R and A43T variants, products of some mutant BCL2 alleles display increased affinity for immobilized Bim and Puma BH3 peptides in vitro (Figs. 5A and 5B) as well as increased binding to these proapoptotic proteins in a cellular context (Fig. 5C) , consistent with BCL2 gain-of-function mutations reported in some lymphoid cell lines. 46, 47 Furthermore, in cell-based assays, these Bcl-2 variants offered more protection from apoptosis induced by Bim EL overexpression (Fig. 5D) . The increased affinity for proapoptotic BH3 domains and enhanced protection was not, however, seen with all variant Bcl-2 proteins, as exemplified by Bcl-2 A82G.
BCL2 mutations correlate with FL clinical course
Examination of patient outcome in the FL discovery cohort revealed a striking decrease in overall survival from diagnosis if a BCL2 mutation was present (Fig. 6A) . Further analysis examined the relationship between BCL2 mutations and outcome in the validation cohort. As shown in Fig. 6B , the presence of a BCL2 mutation at diagnosis was associated with a marked increase in transformation risk compared to absence of a BCL2 mutation [p<0.0001 by log-rank test; hazard ratio (HR) 3.56; 95% CI 1.98-6.17]. This association was even stronger than the relationship between AID expression and transformation risk (HR, 1.70, 95% CI 1.06-3.00; Fig. 6C ). These effects were most prominent in FLs with nonsynonymous mutations (Fig. 6D) .
There was also a striking acceleration of death due to lymphoma (Fig. 6E) 43 there was an excess of nonsynonymous mutations in FL (Fig. 1D) .
Indeed, the vast majority of synonymous BCL2 mutations in FL occur in association with nonsynonymous alterations (Table S3) . Third, some of the mutant Bcl-2 proteins, e.g., Bcl-2 G33R and Bcl-2 A43T, bound and neutralized proapoptotic Bcl-2 family members more effectively (Fig. 5) .
Although we have observed functional consequences of the BCL2 mutations found in certain lymphoma cell lines 46, 47 and in FL (this study), it is important to emphasize that not all of the BCL2 mutations are functionally significant. In particular, we have observed that the conservative A82G mutation has little impact on Bcl-2 function (Fig. 5) . Thus, the situation with BCL2 mutations might be somewhat analogous to BRCA1 or BRCA2 missense mutations, where some
For personal use only. on April 29, 2017 . by guest www.bloodjournal.org From 14 are functionally important and others are not. 56 Additional observations suggest that AID might be involved in the generation of the BCL2 SNVs. First, the vast majority of BCL2 mutations occur at Cs and Gs, consistent with AIDinduced cytidine deamination. Second, BCL2 mutations exhibit a preference for AID target sequences rather than CpG sequences that would be preferred if spontaneous chemical deamination were responsible. Third, higher AID expression was observed in samples with BCL2 mutations at diagnosis (Fig. 3E) .
When the relationship between AID, BCL2 mutations, and survival was examined, transformation correlated with high AID expression (Fig. 6C) and even more strongly with the presence of BCL2 mutations. Initially observed in a prevalence study (Fig. 6A) , this relationship between BCL2 mutations and earlier transformation was independently replicated in a larger, independent study of FL samples uniformly collected at diagnosis (Fig. 6B) . In short, the presence of BCL2 mutations at diagnosis correlated with decreased time to transformation of FL and increased risk of death due to FL (Figs. 6B and 6E) .
We also observed more BCL2 mutations at transformation than at diagnosis (Fig. 4) , possibly reflecting ongoing mutagenic processes in FL. Comparison of the mutations at diagnosis and transformation nonetheless revealed potentially important differences. In particular, those acquired at transformation had a lower frequency of obvious AID signatures (15% at transformation vs 40% at diagnosis, Table S4 ), perhaps reflecting additional effects of intervening therapy or increased AID action at noncanonical sequences. 57 Moreover, some mutations at transformation were clearly nonfunctional, e.g., a BCL2 variant with a premature stop codon at transformation, again emphasizing that not all BCL2 mutations enhance Bcl-2 protein function.
Despite the strong correlation between BCL2 mutations at diagnosis and poor outcome in two
For personal use only. on April 29, 2017 . by guest www.bloodjournal.org From 15 separate cohorts, we are aware of several limitations to the present study. First, the two cohorts differed from each other in important ways. The discovery cohort consisted of FLs with multiple cryopreserved vials decades after diagnosis. Consistent with the possibility that this cohort might have had bulkier disease, twice as many patients in the discovery cohort had FLIPI scores of 3 or 4 at diagnosis ( Table 1 ). The frequency of mutations at diagnosis in this cohort also appeared higher, although the small sample size was small.
Second, in order to have sufficient follow up, the present study utilized cohorts treated almost exclusively in the pre-rituximab era. Accordingly, it will be important in the future to assess whether a similar correlation between BCL2 mutation and poor outcome exists in patients receiving chemoimmunotherapy.
Third, because of our focus on sequence-associated changes in function of the Bcl-2 protein, 46 ,47 the present study differs from other recent efforts to catalog FL mutations. Sanger sequencing, a gold standard for detecting sequence variation, was utilized here. Moreover, the present study focused on BCL2 exons, especially protein encoding exons 2 and 3. This more focused approach likely underestimates the total number of BCL2 mutations compared to studies that utilized much more sensitive sequencing techniques and/or examined more noncoding BCL2 sequence in an effort to identify all mutations in the BCL2 locus. 16, 44, 45 Finally, the present study does not address the question of whether BCL2 mutations cause FL transformation. In our cohort, over 50% of transformed FLs have synonymous mutations or no mutations at all (Fig. 4A) , indicating that BCL2 mutations are not required for FL transformation but leaving open the question of their contribution in transformed FLs that harbor them. In particular, we cannot rule out the possibility that BCL2 mutations are simply a surrogate for AIDinduced mutagenesis. AID has previously been implicated in mutating BCL2, 43 as well as BCL6, MYC, PIM1 and PAX5. 35, 36 In the present study, PIM1 mutations were less frequent than BCL2 16 mutations and did not correlate with early transformation. Moreover, transformation correlated more strongly with BCL2 mutation status (Fig. 6B) than with AID expression (Figs. 6C) .
Nonetheless, further evaluation of AID expression, BCL2 mutation status and disease progression in additional patient cohorts is required to further address this issue. Moreover, even if BCL2 mutations are a reflection of AID activity, they might represent an objective and readily quantifiable measure of AID mutagenesis.
The observation that BCL2 mutation status at diagnosis is an independent prognostic factor in FL that supplements the FLIPI has potentially important implications. High FLIPI score has been associated with transformation in multiple studies. 2, 17, 20, 22, 23, 58 If poor outcome in patients with BCL2-mutant FL is also widely replicated, this might serve as the foundation for further studies in FL. In particular, assessment of BCL2 mutation status along with FLIPI could allow better stratification of FL patients in future clinical trials. In addition, it might also be reasonable to assess the effects of earlier therapeutic intervention, use of agents that bypass the mitochondrial apoptotic pathway, or treatment with Bcl-2 antagonists in this subgroup of FL patients. 
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